New Zealand-based Upside Biotechnologies has launched a new skin replacement treatment in Auckland for patients suffering from major burns.
Using regenerative medicine, new methods can be developed to regrow, repair or replace damaged or diseased cells, organs or tissues to restore or establish normal function.
Go deeper with GlobalData
Upside Biotechnologies has developed the new technology at the University of Auckland’s Rod Dunbar’s laboratory.
Upside Biotechnologies CEO Dr Robert Feldman said: “Upside skin is produced faster than any competitive product in development, and is supplied in larger sheets with excellent handling characteristics that burns surgeons prefer.”
The company has completed a first tranche of equity funding and is currently seeking further investment.
See Also:
To date, the work has received funding from Cure Kids Ventures, Auckland UniServices, the Manchester Trust, the Ministry of Business, Innovation and Employment and The Maurice Wilkins Centre.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUpside’s new technology enables a small sample of unburnt patient skin to be grown in the laboratory into large areas of full thickness skin, which can be used as skin grafts in patients suffering severe burns.
Cure Kids Ventures CEO Maxine Simmons said: “This is a hugely attractive business opportunity.
“A truly compelling healthcare solution that comes from great science and is being run by a world-class team.”
Feldman added: “The technology is superb, the market attractive and backers excellent.”
